Member Info for EmeraldCarrots

People was about. A pilot scheme to hopefully further validate dual analysis would be too much to hope for. Unless Illumina and Angle have made further progress to make it available for "off the shelf" use by other labs........... like the ones in the NHS? Too much to hope for probably, but you never know.

All IMHO.

Astrazeneca and Eisai (all multi $Billion Plc's) to do business with Angle Plc. Wonder who willl be next? Roche? Thermo Fisher?

We need an International sales Director who ideally also speaks at least German or French who has experience is selling medical machines to European Countries. It is obvious. Gino and Russ can have their pay cut to pay the persons wages if you ask me.

Of the MT-RNR1 could hardly be better news to promote International sales, let alone saving babies from going deaf. We hear next to nothing abour these sales. We need an International sales Director with experience selling to the EU. as I suspect Patrick is out of his depth. There are 13,000 hospitals in the European Union and we got the CE mark for the MT-RNR1 several months ago.

All IMHO.

NHS Scotland place an order to rollout the Gebnedrive MT-RNR1 to all neonatal Hospitals. Sensible IMHO. Job done.

Meanwhile NICE for some reason orders the same machines installed at only 14 hospitals in the other NHS countries to further test them for a few years. Each test needs to be done again at an NHS lab to see if it is correct. Just for a few years. So how much is this double testing costing? Blood draw, package up, courier to a lab, run the test, document the result, copy in Genedrive. Waste of NHS cash if you ask me. Ridiculous.

All IMHO.

Guide. Will this guide be published before all the stars in the Universe have burnt their fuel and the Universe is cold and black?

Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

NICE is working with NHS England, who are delivering a national pilot to produce an implementation guide for providers and information to support future commissioning decisions. The pilot ran from October 2024 to May 2025 and the results from this are now being reviewed. We will notify stakeholders when supporting information on implementation is available.

https://www.nice.org.uk/guidance/dg59

These 3 run the Company........... at the moment.

In my opinion Gino should be the technical Director and help out on the sales side.

Patrick maybe for UK and Ireland sales. We got the Scottish order somehow after all. If we had not it would be all over already.

New Director of International sales. Someone with experience of selling medical machines to EU. Countries and ideally the USA.

High pressure position. Share options for success.

Maybe Russ Shaw should be CEO.

He knows where the cash is going and is best place to reduce costs and re-target the rest.

- The directors pay should be cut. 50% cut which will be restored when the audited accounts show a profit.

- Monthly expendature needs reducing.

- Genedrive need to apply for FDA approvalfor the Genedrive® MT-RNR1 THIS YEAR somehow.

The Directors seenm to be clueless as to it's importance to the SHARE PRICE.

If they had done 1 application we would not be in this position as the placing could have been done at more like 3p.

I assume the problem is getting "real world" data from use in USA hospitals?

Maybe the only realistic way would be to do a deal with an existing Hospital medical machive supplier.

They pay all expenses for getting the FDA approval. In return they get an exclusive license for sales in the USA and pay us a royalty for each machine sold.

All IMHO.

RaiseworldC.

"Great. What are they? Thank you."

====================

1. Quality manager.

2. Human Tissue Act Consultant.

- I'm wondering what tissue Angle deal with, or should I say will be dealing with.

Does blood count as tissue? Or are they about to do something involving human tisse samples that they have not done before?

The Myriad Genetics deal is highly likely to get the attention of all genetic testing and Pharma Co's all over the World. If they are worth their salt all these Companies should be abreast of this deal at minimum. They must wonder if they are going to lose out. I believe Angle's Parsortix machine is the best and only machine that can catch live intact CTC's perfect for DNA analysis. The deal is not exclusive, yet so they had better at least contact Angle and do their own evaluation of the CTC's that Parsortix can catch. If they don't then they may have some awkward questions raised by their shareholders. May be VERY, VERY awkward if they are up the creek without a paddle. Parsortix is needed for CTC DNA analysis.

UK's NHS.

It is no secret that Angle Plc want to do deals with the NHS. It appears someone is now listening as apparently NHS people visited Angle some weeks ago. I have no idea what the Angle/NHS meeting was specifically about. We can guess that it may have been about analysing CTC's in breast cancer patients blood to see if the cancer is HER2 positive, low, or negative. AN certainly thinks this test is needed to guide breast cancer treatment, the same test that Eisai used in their cancer drug trial. If the NHS agree to install Parsortix machines in their 7 national hubs it would be the making of Angle Plc, a World class British Plc don't forget. Also It could be the now famous "dual analysis" that Angle pioneered and announced in their RNS dated 4th Jan 2024. If the NHS trial this it will also me the making of Angle Plc. Obviously once Parsortix machines are used in the 7 hubs all the other tests in the pipeline could end up being done.

https://myriad.com/about-myriad-genetics/

https://myriad.com/genetic-tests/precise-tumor/

All IMHO.

I was emailed them by Indeed. If you are a member you can set up an alert.

Lung cancer dual analysis so the NHS find more biomarkers to target with modern drugs?

Her2 analysis to find if the breast cancer is HER 2 positive, low , or negative?

Some sort of PD-L1 analysis?

Good thing is any deal will IMHO lead to more and different tests.

Any NHS deal will do!

All IMHO.

Brewing here.

Are to blame for what seems to be a Company with overpaid directors (and staff?) that have two fantastic products they have no clue how to sell to the EU. or USA. Ian Gilham should be ashamed of all this.

All IMHO.

This Patrick Breen person is simply not delivering the goods. The MT-RNR1 has been CE cleared for several months and astonishingly very few sales seem to have happened. You could hardly wish for better selling ammunition than this machine. They need someone used to selling to hospitals in the EU. I think this is one of their major problems.

All IMHO.

TwoGood2Die.

Stay tuned.

==========

Let's hope its good news.

Is ridiculous like the directors wages. The Directors need to wake up before they are out of a job. Also whatever alse makes up the monthly expendature needs slashing. 2 excellent products, but a vastly overpaid workforce without a sales director (or any sales team?). At the end of the day it's Ian Gilhams fault as much as anyone's.

All IMHO.

Equipment to countries in the EU., assuming they have not already. I don't believe there is an issue with the two products. It's the sales side that is a shambles. I get the impression they go to a few exhibition shows and expect a load of orders to appear. Gino is a Dr, not a CEO. He should be looking after and developing the kit. Quite what Ian Gilham is up to I don't know. I mean, does he want the Company to fail? Why is there no sales Director Ian? Why are Geno and Russ on such high salaries????

All IMHO.

Buyers?

Have to wait if this continues. And Illumina, and Eisai, and Roche, and etc......

I think we are in business!

All IMHO.

Nice. Her2 or dual analysis for starters? Don't know that.